HTDS Stock Overview
Manufactures, supplies, and exports biopharmaceuticals and vaccines in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Hard to Treat Diseases Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.000002 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 0% |
| 3 Year Change | -90.00% |
| 5 Year Change | -99.00% |
| Change since IPO | -99.96% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| HTDS | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0% | 0.7% | -0.2% |
| 1Y | 0% | -10.7% | 25.8% |
Return vs Industry: HTDS exceeded the US Healthcare industry which returned -10.7% over the past year.
Return vs Market: HTDS underperformed the US Market which returned 25.8% over the past year.
Price Volatility
| HTDS volatility | |
|---|---|
| HTDS Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 7.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: HTDS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine HTDS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | n/a | Terry Yuan | www.mellowhope.com |
Hard to Treat Diseases Inc. manufactures, supplies, and exports biopharmaceuticals and vaccines in China and internationally. The company offers biologicals, including reteplase (rPA), mycobacterium vaccae, acutobin urinary kallidinogenase, ulinastatin, and cerebroprotein hydrolysate for injection; chemicals, such as cobratide injection, entecavir capsule, HES, dasatinib tablets, thymosin a1 for injection, imipenem and cilastatin sodium for injection, and meropenem for injection; and vaccines, which include rabies vaccine, ACYW135 meningococcal vaccine, influenza vaccine, Hepatitis A, and varicella vaccine. It markets its products through a sales network that focuses on South Asia, South-east Asia, Central and South America, and the Middle East.
Hard to Treat Diseases Inc. Fundamentals Summary
| HTDS fundamental statistics | |
|---|---|
| Market cap | US$5.82k |
| Earnings (TTM) | US$974.30k |
| Revenue (TTM) | US$6.16m |
0.0x
P/E Ratio0.0x
P/S RatioIs HTDS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HTDS income statement (TTM) | |
|---|---|
| Revenue | US$6.16m |
| Cost of Revenue | US$4.38m |
| Gross Profit | US$1.78m |
| Other Expenses | US$808.52k |
| Earnings | US$974.30k |
Last Reported Earnings
Sep 30, 2010
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did HTDS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 07:29 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2010/09/30 |
| Annual Earnings | 2009/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hard to Treat Diseases Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|